Loading…

Quality of life of patients treated with opium tincture or methadone: A randomized controlled trial

Quality of life (QoL) is an increasingly recognized patient-centered treatment outcome in individuals with opioid use disorder. There is a gap in literature on the impact of opium tincture (OT) on patients’ QoL compared to standard treatment options such as methadone. This study aimed to compare the...

Full description

Saved in:
Bibliographic Details
Published in:Drug and alcohol dependence 2023-08, Vol.249, p.110874-110874, Article 110874
Main Authors: Kim, Jane J., Nikoo, Mohammadali, Nikoo, Nooshin, Javidanbardan, Sanam, Kazemi, Alireza, Choi, Fiona, Gholami, Ali, Lafooraki, Neda Y., Vogel, Marc, Rezazadeh-Azar, Pouya, Meyer, Maximilian, Cabanis, Maurice, Jang, Kerry, Aknondzadeh, Shahin, Krausz, Michael
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c319t-f2fd705635ac58e83d7f05bb4e9c87a9e0ed17e848b4c2af6076e56a1ed9c2ad3
container_end_page 110874
container_issue
container_start_page 110874
container_title Drug and alcohol dependence
container_volume 249
creator Kim, Jane J.
Nikoo, Mohammadali
Nikoo, Nooshin
Javidanbardan, Sanam
Kazemi, Alireza
Choi, Fiona
Gholami, Ali
Lafooraki, Neda Y.
Vogel, Marc
Rezazadeh-Azar, Pouya
Meyer, Maximilian
Cabanis, Maurice
Jang, Kerry
Aknondzadeh, Shahin
Krausz, Michael
description Quality of life (QoL) is an increasingly recognized patient-centered treatment outcome in individuals with opioid use disorder. There is a gap in literature on the impact of opium tincture (OT) on patients’ QoL compared to standard treatment options such as methadone. This study aimed to compare the QoL of participants with opioid use disorder receiving OAT using OT or methadone and identify the factors associated with their QoL during treatment. The opium trial was a multicenter non-inferiority randomized clinical trial in four private OAT outpatient clinics in Iran. The study assigned patients to either OT (10 mg/ml) or methadone sirup (5 mg/ml) for a follow-up of 85 days. QoL was assessed using the brief version of the World Health Organization Quality of Life instrument (WHOQOL- BREF). A total of 83 participants, 35 (42.2%) in the OT arm and 48 (57.8%) in the methadone arm, completed the WHOQOL-BREF in full and were included in the primary analysis. The mean score of patients’ QoL showed improvement compared to baseline, but differences were not statistically significant between OT and methadone arms (p = 0.786). Improvements were mainly observed within the first 30 days of receiving treatment. Being married and lower psychological distress were associated with an improved QoL. Within the social relationships domain, male gender showed significantly higher QoL compared to females. OT shows promise as an OAT medication, comparable to methadone in improving patients’ QoL. There is a need to incorporate psychosocial interventions to further sustain and improve the QoL in this population. Identifying other social determinants of health which affect QoL and the cultural adaptation of assessments for individuals from various ethnocultural backgrounds are critical areas of inquiry. •Treatment with opium tincture and methadone can improve patients’ quality of life.•Improvements were mainly observed within the first month of receiving treatment.•Integrating psychosocial interventions may improve patient outcomes.•Quality of life is an important measure in opioid use disorder treatment.
doi_str_mv 10.1016/j.drugalcdep.2023.110874
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2833647287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871623011122</els_id><sourcerecordid>2833647287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-f2fd705635ac58e83d7f05bb4e9c87a9e0ed17e848b4c2af6076e56a1ed9c2ad3</originalsourceid><addsrcrecordid>eNqFkE1PJCEQholZo7PqXzAcvfQsNN1Ae1PjV2JiTPRMGKhWJnTTC_Sa8dfLZHT3uFyKSp63KvUghClZUkL5r_XSxvlVe2NhWtakZktKiRTNHlpQKbqKkIb_QAvCBK-koPwQ_UxpTcrjHTlAh0w0JcTaBTJPs_Yub3DosXc9bOuks4MxJ5wj6AwWv7v8hsPk5gFnN5o8x8JFPEB-0zaMcI4vcNSjDYP7KLgJY47B-_LN0Wl_jPZ77ROcfNUj9HJz_Xx1Vz083t5fXTxUhtEuV33dW0FazlptWgmSWdGTdrVqoDNS6A4IWCpANnLVmFr3nAgOLdcUbFd6y47Q2W7uFMPvGVJWg0sGvNcjhDmpWjLGG1FLUVC5Q00MKUXo1RTdoONGUaK2itVa_VOstorVTnGJnn5tmVcD2L_Bb6cFuNwBUG794yCqZIpPA9ZFMFnZ4P6_5RPuqJPk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2833647287</pqid></control><display><type>article</type><title>Quality of life of patients treated with opium tincture or methadone: A randomized controlled trial</title><source>ScienceDirect Freedom Collection 2022-2024</source><source>ScienceDirect Journals</source><creator>Kim, Jane J. ; Nikoo, Mohammadali ; Nikoo, Nooshin ; Javidanbardan, Sanam ; Kazemi, Alireza ; Choi, Fiona ; Gholami, Ali ; Lafooraki, Neda Y. ; Vogel, Marc ; Rezazadeh-Azar, Pouya ; Meyer, Maximilian ; Cabanis, Maurice ; Jang, Kerry ; Aknondzadeh, Shahin ; Krausz, Michael</creator><creatorcontrib>Kim, Jane J. ; Nikoo, Mohammadali ; Nikoo, Nooshin ; Javidanbardan, Sanam ; Kazemi, Alireza ; Choi, Fiona ; Gholami, Ali ; Lafooraki, Neda Y. ; Vogel, Marc ; Rezazadeh-Azar, Pouya ; Meyer, Maximilian ; Cabanis, Maurice ; Jang, Kerry ; Aknondzadeh, Shahin ; Krausz, Michael</creatorcontrib><description>Quality of life (QoL) is an increasingly recognized patient-centered treatment outcome in individuals with opioid use disorder. There is a gap in literature on the impact of opium tincture (OT) on patients’ QoL compared to standard treatment options such as methadone. This study aimed to compare the QoL of participants with opioid use disorder receiving OAT using OT or methadone and identify the factors associated with their QoL during treatment. The opium trial was a multicenter non-inferiority randomized clinical trial in four private OAT outpatient clinics in Iran. The study assigned patients to either OT (10 mg/ml) or methadone sirup (5 mg/ml) for a follow-up of 85 days. QoL was assessed using the brief version of the World Health Organization Quality of Life instrument (WHOQOL- BREF). A total of 83 participants, 35 (42.2%) in the OT arm and 48 (57.8%) in the methadone arm, completed the WHOQOL-BREF in full and were included in the primary analysis. The mean score of patients’ QoL showed improvement compared to baseline, but differences were not statistically significant between OT and methadone arms (p = 0.786). Improvements were mainly observed within the first 30 days of receiving treatment. Being married and lower psychological distress were associated with an improved QoL. Within the social relationships domain, male gender showed significantly higher QoL compared to females. OT shows promise as an OAT medication, comparable to methadone in improving patients’ QoL. There is a need to incorporate psychosocial interventions to further sustain and improve the QoL in this population. Identifying other social determinants of health which affect QoL and the cultural adaptation of assessments for individuals from various ethnocultural backgrounds are critical areas of inquiry. •Treatment with opium tincture and methadone can improve patients’ quality of life.•Improvements were mainly observed within the first month of receiving treatment.•Integrating psychosocial interventions may improve patient outcomes.•Quality of life is an important measure in opioid use disorder treatment.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/j.drugalcdep.2023.110874</identifier><identifier>PMID: 37402335</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Iran ; Methadone ; Opioid agonist treatment ; Opioid use disorder ; Opium tincture ; Quality of life</subject><ispartof>Drug and alcohol dependence, 2023-08, Vol.249, p.110874-110874, Article 110874</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c319t-f2fd705635ac58e83d7f05bb4e9c87a9e0ed17e848b4c2af6076e56a1ed9c2ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0376871623011122$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37402335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Jane J.</creatorcontrib><creatorcontrib>Nikoo, Mohammadali</creatorcontrib><creatorcontrib>Nikoo, Nooshin</creatorcontrib><creatorcontrib>Javidanbardan, Sanam</creatorcontrib><creatorcontrib>Kazemi, Alireza</creatorcontrib><creatorcontrib>Choi, Fiona</creatorcontrib><creatorcontrib>Gholami, Ali</creatorcontrib><creatorcontrib>Lafooraki, Neda Y.</creatorcontrib><creatorcontrib>Vogel, Marc</creatorcontrib><creatorcontrib>Rezazadeh-Azar, Pouya</creatorcontrib><creatorcontrib>Meyer, Maximilian</creatorcontrib><creatorcontrib>Cabanis, Maurice</creatorcontrib><creatorcontrib>Jang, Kerry</creatorcontrib><creatorcontrib>Aknondzadeh, Shahin</creatorcontrib><creatorcontrib>Krausz, Michael</creatorcontrib><title>Quality of life of patients treated with opium tincture or methadone: A randomized controlled trial</title><title>Drug and alcohol dependence</title><addtitle>Drug Alcohol Depend</addtitle><description>Quality of life (QoL) is an increasingly recognized patient-centered treatment outcome in individuals with opioid use disorder. There is a gap in literature on the impact of opium tincture (OT) on patients’ QoL compared to standard treatment options such as methadone. This study aimed to compare the QoL of participants with opioid use disorder receiving OAT using OT or methadone and identify the factors associated with their QoL during treatment. The opium trial was a multicenter non-inferiority randomized clinical trial in four private OAT outpatient clinics in Iran. The study assigned patients to either OT (10 mg/ml) or methadone sirup (5 mg/ml) for a follow-up of 85 days. QoL was assessed using the brief version of the World Health Organization Quality of Life instrument (WHOQOL- BREF). A total of 83 participants, 35 (42.2%) in the OT arm and 48 (57.8%) in the methadone arm, completed the WHOQOL-BREF in full and were included in the primary analysis. The mean score of patients’ QoL showed improvement compared to baseline, but differences were not statistically significant between OT and methadone arms (p = 0.786). Improvements were mainly observed within the first 30 days of receiving treatment. Being married and lower psychological distress were associated with an improved QoL. Within the social relationships domain, male gender showed significantly higher QoL compared to females. OT shows promise as an OAT medication, comparable to methadone in improving patients’ QoL. There is a need to incorporate psychosocial interventions to further sustain and improve the QoL in this population. Identifying other social determinants of health which affect QoL and the cultural adaptation of assessments for individuals from various ethnocultural backgrounds are critical areas of inquiry. •Treatment with opium tincture and methadone can improve patients’ quality of life.•Improvements were mainly observed within the first month of receiving treatment.•Integrating psychosocial interventions may improve patient outcomes.•Quality of life is an important measure in opioid use disorder treatment.</description><subject>Iran</subject><subject>Methadone</subject><subject>Opioid agonist treatment</subject><subject>Opioid use disorder</subject><subject>Opium tincture</subject><subject>Quality of life</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkE1PJCEQholZo7PqXzAcvfQsNN1Ae1PjV2JiTPRMGKhWJnTTC_Sa8dfLZHT3uFyKSp63KvUghClZUkL5r_XSxvlVe2NhWtakZktKiRTNHlpQKbqKkIb_QAvCBK-koPwQ_UxpTcrjHTlAh0w0JcTaBTJPs_Yub3DosXc9bOuks4MxJ5wj6AwWv7v8hsPk5gFnN5o8x8JFPEB-0zaMcI4vcNSjDYP7KLgJY47B-_LN0Wl_jPZ77ROcfNUj9HJz_Xx1Vz083t5fXTxUhtEuV33dW0FazlptWgmSWdGTdrVqoDNS6A4IWCpANnLVmFr3nAgOLdcUbFd6y47Q2W7uFMPvGVJWg0sGvNcjhDmpWjLGG1FLUVC5Q00MKUXo1RTdoONGUaK2itVa_VOstorVTnGJnn5tmVcD2L_Bb6cFuNwBUG794yCqZIpPA9ZFMFnZ4P6_5RPuqJPk</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Kim, Jane J.</creator><creator>Nikoo, Mohammadali</creator><creator>Nikoo, Nooshin</creator><creator>Javidanbardan, Sanam</creator><creator>Kazemi, Alireza</creator><creator>Choi, Fiona</creator><creator>Gholami, Ali</creator><creator>Lafooraki, Neda Y.</creator><creator>Vogel, Marc</creator><creator>Rezazadeh-Azar, Pouya</creator><creator>Meyer, Maximilian</creator><creator>Cabanis, Maurice</creator><creator>Jang, Kerry</creator><creator>Aknondzadeh, Shahin</creator><creator>Krausz, Michael</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230801</creationdate><title>Quality of life of patients treated with opium tincture or methadone: A randomized controlled trial</title><author>Kim, Jane J. ; Nikoo, Mohammadali ; Nikoo, Nooshin ; Javidanbardan, Sanam ; Kazemi, Alireza ; Choi, Fiona ; Gholami, Ali ; Lafooraki, Neda Y. ; Vogel, Marc ; Rezazadeh-Azar, Pouya ; Meyer, Maximilian ; Cabanis, Maurice ; Jang, Kerry ; Aknondzadeh, Shahin ; Krausz, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-f2fd705635ac58e83d7f05bb4e9c87a9e0ed17e848b4c2af6076e56a1ed9c2ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Iran</topic><topic>Methadone</topic><topic>Opioid agonist treatment</topic><topic>Opioid use disorder</topic><topic>Opium tincture</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Jane J.</creatorcontrib><creatorcontrib>Nikoo, Mohammadali</creatorcontrib><creatorcontrib>Nikoo, Nooshin</creatorcontrib><creatorcontrib>Javidanbardan, Sanam</creatorcontrib><creatorcontrib>Kazemi, Alireza</creatorcontrib><creatorcontrib>Choi, Fiona</creatorcontrib><creatorcontrib>Gholami, Ali</creatorcontrib><creatorcontrib>Lafooraki, Neda Y.</creatorcontrib><creatorcontrib>Vogel, Marc</creatorcontrib><creatorcontrib>Rezazadeh-Azar, Pouya</creatorcontrib><creatorcontrib>Meyer, Maximilian</creatorcontrib><creatorcontrib>Cabanis, Maurice</creatorcontrib><creatorcontrib>Jang, Kerry</creatorcontrib><creatorcontrib>Aknondzadeh, Shahin</creatorcontrib><creatorcontrib>Krausz, Michael</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Jane J.</au><au>Nikoo, Mohammadali</au><au>Nikoo, Nooshin</au><au>Javidanbardan, Sanam</au><au>Kazemi, Alireza</au><au>Choi, Fiona</au><au>Gholami, Ali</au><au>Lafooraki, Neda Y.</au><au>Vogel, Marc</au><au>Rezazadeh-Azar, Pouya</au><au>Meyer, Maximilian</au><au>Cabanis, Maurice</au><au>Jang, Kerry</au><au>Aknondzadeh, Shahin</au><au>Krausz, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of life of patients treated with opium tincture or methadone: A randomized controlled trial</atitle><jtitle>Drug and alcohol dependence</jtitle><addtitle>Drug Alcohol Depend</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>249</volume><spage>110874</spage><epage>110874</epage><pages>110874-110874</pages><artnum>110874</artnum><issn>0376-8716</issn><eissn>1879-0046</eissn><abstract>Quality of life (QoL) is an increasingly recognized patient-centered treatment outcome in individuals with opioid use disorder. There is a gap in literature on the impact of opium tincture (OT) on patients’ QoL compared to standard treatment options such as methadone. This study aimed to compare the QoL of participants with opioid use disorder receiving OAT using OT or methadone and identify the factors associated with their QoL during treatment. The opium trial was a multicenter non-inferiority randomized clinical trial in four private OAT outpatient clinics in Iran. The study assigned patients to either OT (10 mg/ml) or methadone sirup (5 mg/ml) for a follow-up of 85 days. QoL was assessed using the brief version of the World Health Organization Quality of Life instrument (WHOQOL- BREF). A total of 83 participants, 35 (42.2%) in the OT arm and 48 (57.8%) in the methadone arm, completed the WHOQOL-BREF in full and were included in the primary analysis. The mean score of patients’ QoL showed improvement compared to baseline, but differences were not statistically significant between OT and methadone arms (p = 0.786). Improvements were mainly observed within the first 30 days of receiving treatment. Being married and lower psychological distress were associated with an improved QoL. Within the social relationships domain, male gender showed significantly higher QoL compared to females. OT shows promise as an OAT medication, comparable to methadone in improving patients’ QoL. There is a need to incorporate psychosocial interventions to further sustain and improve the QoL in this population. Identifying other social determinants of health which affect QoL and the cultural adaptation of assessments for individuals from various ethnocultural backgrounds are critical areas of inquiry. •Treatment with opium tincture and methadone can improve patients’ quality of life.•Improvements were mainly observed within the first month of receiving treatment.•Integrating psychosocial interventions may improve patient outcomes.•Quality of life is an important measure in opioid use disorder treatment.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>37402335</pmid><doi>10.1016/j.drugalcdep.2023.110874</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0376-8716
ispartof Drug and alcohol dependence, 2023-08, Vol.249, p.110874-110874, Article 110874
issn 0376-8716
1879-0046
language eng
recordid cdi_proquest_miscellaneous_2833647287
source ScienceDirect Freedom Collection 2022-2024; ScienceDirect Journals
subjects Iran
Methadone
Opioid agonist treatment
Opioid use disorder
Opium tincture
Quality of life
title Quality of life of patients treated with opium tincture or methadone: A randomized controlled trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T01%3A38%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20life%20of%20patients%20treated%20with%20opium%20tincture%20or%20methadone:%20A%20randomized%20controlled%20trial&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Kim,%20Jane%20J.&rft.date=2023-08-01&rft.volume=249&rft.spage=110874&rft.epage=110874&rft.pages=110874-110874&rft.artnum=110874&rft.issn=0376-8716&rft.eissn=1879-0046&rft_id=info:doi/10.1016/j.drugalcdep.2023.110874&rft_dat=%3Cproquest_cross%3E2833647287%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c319t-f2fd705635ac58e83d7f05bb4e9c87a9e0ed17e848b4c2af6076e56a1ed9c2ad3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2833647287&rft_id=info:pmid/37402335&rfr_iscdi=true